Core Insights - Dongxing Medical (301290.SZ) reported its Q3 2025 results on October 29, 2025, highlighting a total of 8 institutional investors holding shares, amounting to 15.50% of the total share capital [1] Institutional Holdings - As of October 28, 2025, institutional investors collectively held 15.52 million shares of Dongxing Medical, a decrease of 1.36 percentage points compared to the previous quarter [1] - The institutional investors include various firms such as Changzhou Kaizhou Investment Management Co., Suzhou Jifeng Equity Investment Partnership, and Hainan Ping An Private Fund Management Co. [1] Public Fund Disclosures - In this reporting period, 32 public funds were not disclosed compared to the previous quarter, including funds like CITIC Jiankong Rotation Mixed A and Medical Device ETF [1]

Group 1 - Dongxing Medical (SZ 301290, closing price: 27.34 yuan) announced on October 29 that its fourth board meeting was held on October 28, 2025, to review the proposal regarding the full text of the "2025 Q3 Report" [1] - For the first half of 2025, Dongxing Medical's revenue composition was 82.23% from the medical device industry and 17.77% from other industries [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after ten years of stagnation, with technology leading the market and a new "slow bull" pattern emerging [1]

Core Insights - Dongxing Medical (301290) reported a revenue of 284 million yuan for the first three quarters of 2025, a year-on-year decline of 10.21%, with a net profit attributable to shareholders of -70 million yuan, down 263% year-on-year, primarily due to a goodwill impairment loss of approximately 100 million yuan recognized in the third quarter [1] Group 1: Business Performance - The company focuses on surgical medical devices, particularly in the field of anastomosis devices, and has two main business segments: surgical instruments represented by anastomosis devices and surgical equipment represented by operating tables and shadowless lamps [1] - In the anastomosis device sector, Dongxing Medical has emphasized the electric anastomosis device, achieving over 130% year-on-year revenue growth in 2024 [1] - The company has obtained a Class III medical device registration certificate for its self-developed fully electric laparoscopic anastomosis device, further solidifying its market position [1] Group 2: Market Trends - Industry data indicates that the anastomosis device market in China is expected to grow from 9.82 billion yuan in 2024 to 16.67 billion yuan by 2030, with electric laparoscopic anastomosis devices being a major growth driver, projected to have a compound annual growth rate of 16% during this period [1] Group 3: Strategic Initiatives - Dongxing Medical is actively expanding into synthetic biology by collaborating with research institutions such as Changzhou University and Shanghai Jiao Tong University to develop high-tech barrier materials like recombinant humanized collagen and mussel adhesive protein, aiming to launch innovative medical consumables for hemostasis and scar repair [2] - The company announced a significant advancement in its platform strategy by planning to acquire 90% of Wuhan Yijiaobao, which will allow it to enter the high-end orthopedic market and extend its industrial chain in surgical medical devices [3] - The acquisition is expected to accelerate the commercialization of synthetic biological materials and enhance the company's platform development [3]

证券代码：301290 证券简称：东星医疗 公告编号：2025-045 江苏东星智慧医疗科技股份有限公司 关于2025年第三季度报告披露的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司(以下简称"公司")于2025年10月28日 召开第四届董事会第十三次会议，审议通过了《关于公司<2025年第三季度报告> 全文的议案》。 为使投资者全面了解公司2025年第三季度的经营成果及财务状况，公司《 2025年第三季度报告》全文于2025年10月29日在中国证券监督管理委员会指定 的创业板信息披露网站巨潮资讯网(www.cninfo.com.cn)上进行披露。 董事会 2025年10月29日 敬请广大投资者注意查阅。 特此公告。 江苏东星智慧医疗科技股份有限公司 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）于2025年10月28 日召开第四届董事会第十三次会议，审议通过了《关于2025年第三季度计提资产 减值准备的议案》，根据《深圳证券交易所上市公司自律监管指引第2号——创 业板上市公司规范运作》《企业会计准则第8号——资产减值》及公司会计政策 等相关规定，公司拟对截至2025年9月30日合并财务报表范围内可能发生减值迹 象的相关资产计提减值准备，该事项在公司董事会审批权限范围内，无需提交公 司股东会审议。现将具体情况公告如下： 一、本次拟计提资产减值准备的情况概述 经公司及下属子公司对截至2025年9月30日可能存在减值迹象的各类资产进行 全面检查和减值测试后，基于谨慎性原则，公司2025年第三季度拟计提信用减值准 备128.70万元，转回信用减值准备127.19万元，计提资产减值准备10,365.33万元，转 回资产减值准备0.48万元，具体明细如下： 单位：万元 | 项目名称 | 2025年6月30日 | 本期变动金额 | | 期末账面余额 | | --- ...

证券代码：301290 证券简称：东星医疗 公告编号：2025-047 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第四届董事会第 十三次会议于 2025 年 10 月 28 日 10:00 在公司会议室以现场结合通讯的方式召 开。本次会议通知已于 2025 年 10 月 24 日通过邮件的方式送达全体董事。本次 会议应出席董事 8 人，实际出席董事 8 人，其中独立董事沈世娟女士、朱旗先生、 上官俊杰先生以通讯方式出席会议。会议由董事长万世平先生召集并主持，公司 高级管理人员列席了本次董事会。本次会议的召集、召开和表决程序符合《中华 人民共和国公司法》（以下简称"《公司法》"）等有关法律法规及《公司章程》 的相关规定。 二、董事会会议审议情况 江苏东星智慧医疗科技股份有限公司 第四届董事会第十三次会议决议公告 根据《公司法》等法律法规、规范性文件及《公司章程》的规定，结合公司 实际经营情况，公司编制了《2025 年第三季度报告》。 经审核，董事会认为公司《2025 年第三季度报告 ...

Core Insights - Dongxing Medical reported a third-quarter revenue of 100 million yuan, a year-on-year decrease of 1.97% [1] - The net profit for the third quarter was a loss of 83.4945 million yuan [1] - For the first three quarters, the revenue totaled 284 million yuan, reflecting a year-on-year decline of 10.21% [1] - The net profit for the first three quarters was a loss of 53.2016 million yuan [1]

Financial Performance - The company's operating revenue for Q3 2025 was ¥100,445,210.23, representing a decrease of 1.97% compared to the same period last year[5] - The net profit attributable to shareholders was -¥83,494,508.46, a significant decline of 566.49% year-on-year[5] - The net profit after deducting non-recurring gains and losses was -¥88,655,148.99, down 834.63% from the previous year[5] - The net profit for the current period is -53,521,791.79, compared to a profit of 65,446,579.46 in the previous period, indicating a significant decline[25] - Operating profit for the current period is -42,533,744.96, down from 78,640,550.02 in the previous period[25] - The company reported a total comprehensive loss of -53,521,791.79 for the current period, compared to a comprehensive income of 65,446,579.46 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,399,532,273.08, a decrease of 3.34% from the end of the previous year[5] - The company's cash and cash equivalents decreased to CNY 49,091,596.87 from CNY 295,179,331.27, representing a decline of 83.42%[20] - Total liabilities increased to CNY 258,354,065.39 from CNY 228,880,540.24, an increase of 12.87%[22] - The company's equity attributable to shareholders decreased to CNY 2,132,288,193.82 from CNY 2,246,597,316.84, a decrease of 5.08%[22] - Non-current assets decreased to CNY 940,317,332.02 from CNY 1,058,892,323.48, a decline of 11.16%[20] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥48,009,972.24, down 43.72% compared to the same period last year[5] - The net cash flow from operating activities is 48,009,972.24, a decrease from 85,301,119.49 in the previous period[26] - Cash received from borrowings increased significantly by 914.16% to ¥111,557,740 from ¥11,000,000, reflecting an increase in bank loans[13] - Cash used for debt repayment surged by 22,735.75% to ¥45,671,492 from ¥200,000, mainly due to increased bank loan repayments[13] - Investment activities resulted in a net cash outflow of -123,932,844.26, compared to -405,944,489.34 in the previous period[27] Expenses and Costs - The company reported a significant increase in financial expenses, totaling ¥499,615.92, an increase of 118.10% due to higher bank loan interest payments[11] - Investment income decreased by 31.95% to ¥18,893,562.47, primarily due to reduced interest from financial products[11] - Total operating costs amounted to CNY 245,520,282.82, down 7.66% from CNY 265,917,172.26 in the previous period[24] Shareholder Information - The total number of shareholders holding ordinary shares is significant, with the largest shareholder holding 25.02% of the shares[16] Development and Strategy - The company has increased its development expenditure by 100% to ¥2,100,000.00, reflecting investment in new product development[10] - The company plans to continue focusing on market expansion and new product development strategies[19] Other Financial Metrics - Basic and diluted earnings per share for the current period are both -0.53, compared to 0.66 in the previous period[26] - The company did not undergo an audit for the third quarter financial report[28]

Group 1 - The core point of the article is that Dongxing Medical (301290) reported a total of 10,933 shareholders as of October 20, 2025, including credit accounts [1]

证券代码：301290 证券简称：东星医疗 公告编号：2025-043 江苏东星智慧医疗科技股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、交易概述 2、本次交易存在不确定性，可能出现因外部环境变化导致交易条件发生变化， 进而导致交易终止的情况。敬请广大投资者注意投资风险。 3、根据《上市公司股票停复牌规则》《深圳证券交易所上市公司自律监管指引 第 6 号——停复牌》的相关规定，本次筹划事项公司股票不停牌。公司将根据相关 事项的进展情况，分阶段及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 江苏东星智慧医疗科技股份有限公司董事会 江苏东星智慧医疗科技股份有限公司（以下简称"公司"或"上市公司"） 拟以支付现金方式购买武汉医佳宝生物材料有限公司（以下简称"武汉医佳宝" 或"标的公司"）90%的股权（以下简称"本次交易"），本次交易如能顺利实 施，武汉医佳宝将成为公司的控股子公司。 根据初步研究和测算，本次交易预计构成《上市公司重大资产重组管理办法》 规定的重大资产重组。本次交易不涉及上市公司发行股 ...